January 14, 2016Platelets
Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry
Key result
Switching from ticagrelor to clopidogrel occurred in 17% of patients, mostly due to need for oral anticoagulation or bleeding, with no ischemic adverse events observed in the 10 days post-switch.
Why the study?
Does switching from ticagrelor to clopidogrel increase ischemic and bleeding events in patients initially treated with ticagrelor?
Population
586 patients treated with ticagrelor in a single center, of which 101 (17%) were switched to clopidogrel.
Comparison
Switching from ticagrelor to clopidogrel through… vs Patients remaining on ticagrelor
Design
Cohort
Follow-up
12 months
Authors
Discussion
Loading...
Member takes
Implication
Supports short-term de-escalation feasibility when indicated; leaves open need for randomized confirmation.
Study Design
Type
Observational (n=586)
Multicenter
No
Structured PICO
Does switching from ticagrelor to clopidogrel increase ischemic and bleeding events in patients initially treated with ticagrelor?
P
Population
586 patients treated with ticagrelor, of whom 101 were switched to clopidogrel and followed for 12 months.
E
Exposure
Switching from ticagrelor to clopidogrel through a standardized protocol
C
Comparator
Patients remaining on ticagrelor ('non-switched' group)
O
Outcome
Ischemic and bleeding events over 12 months follow-upsafety
Switching from ticagrelor to clopidogrel using a standardized protocol appears safe without an increase in short-term ischemic events.
Limitations
- Larger studies are needed to validate the findings
- larger studies are needed to validate our findings
Cite This Study
Biscaglia et al. (2016) conducted an observational in Patients treated with ticagrelor (n=586). Switching from ticagrelor to clopidogrel vs. Continued ticagrelor (non-switched group) was evaluated on Ischemic and bleeding events. Switching from ticagrelor to clopidogrel occurred in 17% of patients, mostly due to need for oral anticoagulation or bleeding, with no ischemic adverse events observed in the 10 days post-switch.